XML 37 R30.htm IDEA: XBRL DOCUMENT
v3.21.4

SHARE CAPITAL (Narrative) (Details) |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 06, 2021 CAD ($) $ / shares shares | Feb. 08, 2021 shares | Feb. 03, 2021 CAD ($) shares | Jan. 06, 2021 CAD ($) $ / shares shares | Nov. 02, 2020 CAD ($) $ / shares shares | Sep. 21, 2021 shares Year $ / shares | Jun. 15, 2021 shares Year $ / shares | Apr. 28, 2021 CAD ($) shares Year $ / shares | Apr. 23, 2021 CAD ($) $ / shares shares | Mar. 17, 2021 CAD ($) Year $ / shares $ / Shares shares | Jan. 21, 2021 Shares | Jan. 19, 2021 CAD ($) shares | Nov. 17, 2020 shares Year $ / shares | Oct. 31, 2020 $ / shares shares | Sep. 30, 2020 CAD ($) $ / shares shares | Jul. 23, 2020 CAD ($) shares Year $ / shares | Jul. 31, 2019 shares | Jul. 30, 2019 CAD ($) $ / shares $ / Shares shares | Sep. 30, 2021 CAD ($) shares $ / shares | Sep. 30, 2020 CAD ($) shares $ / shares | Sep. 28, 2020 CAD ($) | Jan. 28, 2021 shares | Sep. 18, 2020 CAD ($) | Jul. 11, 2020 $ / shares | Sep. 30, 2019 $ / shares
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of issued and outstanding common shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | On November 10, 2020, the Directors of the Company approved the consolidation of the Company's issued and outstanding common shares on a 2.5:1 basis. |  |  |  |  |  |
Number of shares issued during period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,049,000 |  |  |  |  |  |  |  |
Shares issued price per share | $ / shares |  |  |  |  |  |  |  | $ 5.85 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issue of ordinary shares | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 80,980 |  |  |  |
Number of units issued |  |  |  |  |  |  |  |  |  | 3,419,883 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Units issued, price per unit | $ / Shares |  |  |  |  |  |  |  |  |  | 7.57 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds from units issued | $ |  |  |  |  |  |  |  |  |  | $ 25,888,514 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants exercise price | $ / shares |  |  |  |  | $ 0.125 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.05 |
Minimum daily volume weighted average trading share price on the CSE | $ / shares |  |  |  |  |  |  |  |  |  | $ 13.25 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Underwriters fees paid | $ |  |  |  |  |  |  |  |  |  | $ 916,317 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued to the University (shares) |  |  |  |  |  |  |  | 63,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued to the University | $ |  |  |  |  |  |  |  | $ 368,550 |  |  |  |  |  |  |  |  |  |  | $ 368,550 |  |  |  |  |  |
Subscription received | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 147,426 |  |  |  | $ 0 | $ 147,426 |  |  |  |  |
Number of common shares subscribed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 294,852 |  |  |  |  |  |
Exercise price, warrants granted | $ / shares |  |  |  |  |  |  |  |  |  | $ 9.46 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Second tranche of a non-brokered private placement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued during period |  |  |  |  | 1,629,138 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued price per share | $ / shares |  |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issue of ordinary shares | $ |  |  |  |  | $ 2,036,422 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Special Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds for warrants issued | $ |  |  |  |  | $ 22,875 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrants deemed to be exercised |  |  | 16,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrants, Issued |  |  |  |  | 18,300 |  |  |  |  |  |  |  |  | 18,300 |  |  |  |  |  |  |  |  |  |  |
Warrants issued, price per warrant | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |  |  |
Number of issued warrants rescinded |  |  |  |  |  |  |  |  |  |  |  | 2,300 |  |  |  |  |  |  |  |  |  |  |  |  |
Refund from issued warrants rescinded | $ |  |  |  |  |  |  |  |  |  |  |  | $ 2,875 |  |  |  |  |  |  |  |  |  |  |  |  |
Amount of escrow proceeds released | $ |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrants, Issued | 8,807 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,709,938 | 4,079,600 |  |  |  |  |
Weighted average exercise price of warrants issued | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 9.46 | $ 0.05 |  |  |  |  |
Warrants exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.05 |  |  |  | $ 4.35 | $ 0.05 |  |  |  |  | $ 0
Warrant ascribed value | $ | $ 33,100 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrants exercised |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,948,000 |  |  |  |  |  |
Weighted average exercise price, Exercised | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.05 |  |  |  |  |  |
Term of warrant | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price, warrants granted | $ / shares | $ 7.57 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average remaining contractual life of outstanding warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years 7 months 28 days | 3 years 9 months 29 days |  |  |  |  |
Threshold percentage of warrants |  |  |  |  |  |  | 4.99% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrowed share purchase warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrants exercised |  |  |  |  |  |  |  |  | 1,948,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average exercise price, Exercised | $ / shares |  |  |  |  |  |  |  |  | $ 0.05 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds from warrants exercised | $ |  |  |  |  |  |  |  |  | $ 97,400 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
First tranche of a non-brokered private placement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued during period |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 623,941 |  |  |  |  |  |  |  |  |  |
Shares issued price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.25 |  |  |  |  | $ 1.25 |  |  |  |  |
Proceeds from issue of ordinary shares | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 779,924 |  |  |  |  |  |  |  |  |  |
Non-brokered private placement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of units issued |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,079,600 |  |  |  |  |  |  |
Units issued, price per unit | $ / Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.05 |  |  |  |  |  |  |
Gross proceeds from units issued | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 203,980 | $ 80,980 |  |  |  |  |  |
Weighted average exercise price of warrants issued | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.05 |  |  |  |  |  |  |
Stock Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of outstanding shares authorized under stock option plan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 895,807 | 150,000 |  |  |  |  |
Weighted average exercise price of options granted | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4.29 | $ 1.25 |  |  |  |  |
Number of options cancelled |  |  |  |  |  |  |  |  |  |  | 20,000 |  |  |  |  |  |  |  | 20,000 |  |  |  |  |  |
Weighted average remaining contractual life of outstanding share options |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4 years 3 months 10 days | 4 years 9 months 21 days |  |  |  |  |
Restricted Share Units [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value of equity settled RSUs granted | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 475,000 |  |  |  |  |
Consultant [Member] | Stock Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  | 8,807 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price, stock options granted | $ / shares |  |  |  |  |  | $ 7.64 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price, stock options granted | $ / shares |  |  |  |  |  | $ 7.64 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option life, stock options granted | Year |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility rate, stock options granted |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Discount rate, stock options granted |  |  |  |  |  | 0.55% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average exercise price of options granted | $ / shares |  |  |  |  |  | $ 7.64 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consultant [Member] | Stock Options [Member] | On December 21, 2021 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consultant [Member] | Stock Options [Member] | On March 21, 2022 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consultant [Member] | Stock Options [Member] | On June 21, 2022 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consultant [Member] | Stock Options [Member] | On September 21, 2022 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Underwriters [Member] | Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrants, Issued |  |  |  |  |  |  |  |  |  | 132,666 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant ascribed value | $ |  |  |  |  |  |  |  |  |  | $ 521,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of share purchase warrants |  |  |  |  |  |  |  |  |  | 521,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price, warrants granted | $ / shares |  |  |  |  |  |  |  |  |  | $ 7.57 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price, warrants granted | $ / shares |  |  |  |  |  |  |  |  |  | $ 6.65 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated life, warrants granted | Year |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected volatility, warrants granted |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Discount rate, warrants granted |  |  |  |  |  |  |  |  |  | 0.35% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Investors [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issue of ordinary shares | $ | $ 13,333,333 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent cash fee | $ | $ 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of equity proceeds received from three investors | 4.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  |  |  |  |  |  | 467,000 |  |  |  |  |  |  |  |  |  |  |  |
Exercise price, stock options granted | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |  |  |  |
Share price, stock options granted | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |  |  |  |
Option life, stock options granted | Year |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |
Volatility rate, stock options granted |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |
Discount rate, stock options granted |  |  |  |  |  |  |  |  |  |  |  |  | 0.43% |  |  |  |  |  |  |  |  |  |  |  |
Weighted average exercise price of options granted | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options One [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  |  |  |  |  |  | 25,000 |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options One [Member] | On the date of grant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  |  |  |  |  |  | 14,000 |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the Company's listing date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the first anniversary of the listing date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Two [Member] | On the second anniversary of the listing date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  |  |  |  |  |  | 4,000 |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member] | On the Company's listing date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Three [Member] | On the six-month anniversary of the listing date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  |  |  |  |  |  | 424,000 |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the first anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the second anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |
Chief Financial Officer, two directors and seven consultants [Member] | Stock Options Four [Member] | On the third anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  |  |  |  |  |  | 33.00% |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  | 240,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price, stock options granted | $ / shares |  |  |  |  |  |  |  | $ 7.60 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price, stock options granted | $ / shares |  |  |  |  |  |  |  | $ 5.98 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option life, stock options granted | Year |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility rate, stock options granted |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Discount rate, stock options granted |  |  |  |  |  |  |  | 0.92% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average exercise price of options granted | $ / shares |  |  |  |  |  |  |  | $ 7.60 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options One [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  | 160,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options One [Member] | On the first anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options One [Member] | On the second anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options One [Member] | On the third anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options One [Member] | On the fourth anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options Two [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  | 80,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options Two [Member] | On the first anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options Two [Member] | On the second anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options Two [Member] | On the six-month anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Three Consultants [Member] | Stock Options Two [Member] | On the eighteen-month anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Director and Consultant [Member] | Stock Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  | 180,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price, stock options granted | $ / shares |  |  |  |  |  |  | $ 7.60 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share price, stock options granted | $ / shares |  |  |  |  |  |  | $ 5.55 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option life, stock options granted | Year |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Volatility rate, stock options granted |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Discount rate, stock options granted |  |  |  |  |  |  | 0.84% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average exercise price of options granted | $ / shares |  |  |  |  |  |  | $ 7.60 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Director and Consultant [Member] | Stock Options [Member] | On the first anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Director and Consultant [Member] | Stock Options [Member] | On the second anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Director and Consultant [Member] | Stock Options [Member] | On the third anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Director and Consultant [Member] | Stock Options [Member] | On the fourth anniversary of the grant date [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Vesting percentage |  |  |  |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Chief Medical Officer [Member] | Stock Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of options granted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |
Exercise price, stock options granted | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |
Share price, stock options granted | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |
Option life, stock options granted | Year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |  |  |  |  |
Volatility rate, stock options granted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |
Discount rate, stock options granted |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.35% |  |  |  |  |  |  |  |  |
Chief Medical Officer [Member] | Restricted Share Units [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of RSU | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 150,000 |  |  |  |  |  |  | $ 230,000 |  |
Debt Settlement Agreement [Member] | Consultant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued during period |  |  |  | 14,799 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued price per share | $ / shares |  |  |  | $ 1.25 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Debt settled through issuance of shares | $ |  |  |  | $ 18,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrowed securities to be released once shares are listed on Canadian Stock Exchange |  | 480,080 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrowed securities to be released after listing date |  | 720,120 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow Agreement [Member] | Warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of classes of share capital [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of common shares deposited to be held in escrow |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,852,800 |  |  |
Number of warrants deposited to be held in escrow |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,948,000 |  |  |
Aggregate securities deposited to be held in escrow |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,800,800 |  |  |

X
- Definition Aggregate securities deposited to be held in escrow. + References No definition available. + Details
Name: | drug_AggregateSecuritiesDepositedToBeHeldInEscrow
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of escrow proceeds released. + References No definition available. + Details
Name: | drug_AmountOfEscrowProceedsReleased
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Information about contingent cash fee. + References No definition available. + Details
Name: | drug_ContingentCashFee
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents amount of debt settled through issuance of shares. + References No definition available. + Details
Name: | drug_DebtSettledThroughIssuanceOfShares
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Description of issued and outstanding common shares. + References No definition available. + Details
Name: | drug_DescriptionOfIssuedAndOutstandingCommonShares
Namespace Prefix: | drug_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Discount rate of warrants granted. + References No definition available. + Details
Name: | drug_DiscountRateOfWarrantsGranted
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of discount rate of stock option granted. + References No definition available. + Details
Name: | drug_DiscountRateStockOptionGranted
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents number of escrowed securities to be released after listing date. + References No definition available. + Details
Name: | drug_EscrowedSecuritiesToBeReleasedAfterListingDate
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents escrowed securities to be released once shares are listed on Canadian Stock Exchange. + References No definition available. + Details
Name: | drug_EscrowedSecuritiesToBeReleasedOnceSharesAreListedOnCanadianStockExchange
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Estimated fair value of equity settled RSUs granted. + References No definition available. + Details
Name: | drug_EstimatedFairValueOfEquitySettledRsusGranted
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Estimated life of warrants granted. + References No definition available. + Details
Name: | drug_EstimatedLifeOfWarrantsGranted
Namespace Prefix: | drug_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price, warrants granted. + References No definition available. + Details
Name: | drug_ExercisePriceWarrantsGranted
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expected volatility of warrants granted. + References No definition available. + Details
Name: | drug_ExpectedVolatilityWarrantsGranted
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents fair value of warrants. + References No definition available. + Details
Name: | drug_FairValueOfWarrants
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of gross proceeds from units issued. + References No definition available. + Details
Name: | drug_GrossProceedsFromUnitsIssued
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represent the gross proceeds from warrants exercised. + References No definition available. + Details
Name: | drug_GrossProceedsFromWarrantsExercised
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) through shares issued to university. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughSharesIssuedToUniversity
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) through shares issued to university shares. + References No definition available. + Details
Name: | drug_IncreaseDecreaseThroughSharesIssuedToUniversityShares
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of issuance of restricted stock units. + References No definition available. + Details
Name: | drug_IssuanceOfRestrictedStockUnits
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- Definition Issue price per share. + References No definition available. + Details
Name: | drug_IssuePricePerShare
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The minimum daily volume weighted average trading share price. + References No definition available. + Details
Name: | drug_MinimumDailyVolumeWeightedAverageTradingSharePrice
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of common shares deposited to be held in escrow. + References No definition available. + Details
Name: | drug_NumberOfCommonSharesDepositedToBeHeldInEscrow
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of common shares subscribed. + References No definition available. + Details
Name: | drug_NumberOfCommonSharesSubscribed
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of issued warrants rescinded. + References No definition available. + Details
Name: | drug_NumberOfIssuedWarrantsRescinded
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of units issued. + References No definition available. + Details
Name: | drug_NumberOfUnitsIssued
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants deemed to be exercised. + References No definition available. + Details
Name: | drug_NumberOfWarrantsDeemedToBeExercised
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of warrants deposited to be held in escrow. + References No definition available. + Details
Name: | drug_NumberOfWarrantsDepositedToBeHeldInEscrow
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represent the number of warrants exercised. + References No definition available. + Details
Name: | drug_NumberOfWarrantsExercised
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of warrants Issued. + References No definition available. + Details
Name: | drug_NumberOfWarrantsIssued
Namespace Prefix: | drug_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of equity proceeds received from three investors. + References No definition available. + Details
Name: | drug_PercentageOfNetEquityProceedsReceivedFromThreeInvestors
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents percentage of outstanding shares authorized under stock option plan. + References No definition available. + Details
Name: | drug_PercentageOfOutstandingSharesAuthorizedUnderStockOptionPlan
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents amount of proceeds for warrants issued. + References No definition available. + Details
Name: | drug_ProceedsForWarrantsIssued
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refund from issued warrants rescinded. + References No definition available. + Details
Name: | drug_RefundFromIssuedWarrantsRescinded
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the amount of subscriptions received. + References No definition available. + Details
Name: | drug_SubscriptionsReceived
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Information about term of warrant. + References No definition available. + Details
Name: | drug_TermOfWarrant
Namespace Prefix: | drug_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Threshold percentage of warrants. + References No definition available. + Details
Name: | drug_ThresholdPercentageOfWarrants
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Underwriters fees paid. + References No definition available. + Details
Name: | drug_UnderwritersFeesPaid
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents unit issued price per unit. + References No definition available. + Details
Name: | drug_UnitsIssuedPricePerUnit
Namespace Prefix: | drug_
Data Type: | srt-types:perUnitItemType
Balance Type: | na
Period Type: | instant

X
- Definition Vesting percentage of share-based payment award. + References No definition available. + Details
Name: | drug_VestingPercentage
Namespace Prefix: | drug_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrant ascribed value. + References No definition available. + Details
Name: | drug_WarrantAscribedValue
Namespace Prefix: | drug_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents per share price of warrants issued. + References No definition available. + Details
Name: | drug_WarrantsIssuedPricePerWarrant
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the weighted average exercise price of warrants exercised In share based payment arrangement. + References No definition available. + Details
Name: | drug_WeightedAverageExercisePriceOfWarrantsExercisedInShareBasedPaymentArrangement
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the weighted average exercise price of warrants issued In share based payment arrangement. + References No definition available. + Details
Name: | drug_WeightedAverageExercisePriceOfWarrantsIssuedInShareBasedPaymentArrangement
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the weighted average exercise price of warrants outstanding in share based payment arrangement. + References No definition available. + Details
Name: | drug_WeightedAverageExercisePriceOfWarrantsOutstandingInShareBasedPaymentArrangement
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The weighted average remaining contractual life of other equity instruments. + References No definition available. + Details
Name: | drug_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments
Namespace Prefix: | drug_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average share price, warrants granted. + References No definition available. + Details
Name: | drug_WeightedAverageSharePriceWarrantsGranted
Namespace Prefix: | drug_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The option life of share options granted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_DescriptionOfOptionLifeShareOptionsGranted
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfClassesOfShareCapitalLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The exercise price of share options granted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_ExercisePriceShareOptionsGranted2019
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 79 -Subparagraph a -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_79_a_iv&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of share options forfeited in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_iii&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of share options granted in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -Subparagraph b -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_ii&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 7 -IssueDate 2020-01-01 -Paragraph 17 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_17&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_ProceedsFromIssueOfOrdinaryShares
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -Subparagraph b -Clause ii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_b_ii&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 45 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_45_d&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2020-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2020-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019
Namespace Prefix: | ifrs-full_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_SecondTrancheOfNonBrokeredPrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_SpecialWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_WarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_EscrowedSharePurchaseWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_FirstTrancheOfNonBrokeredPrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_NonBrokeredPrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_StockOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfShareCapitalAxis=drug_RestrictedShareUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ConsultantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_TwelfthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_ThirteenthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_FourteenthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_FifteenthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=drug_UnderwritersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeInvestorsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ChiefFinancialOfficerTwoDirectorsAndSevenConsultantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_StockOptionAxis=drug_StockOptionsOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_FirstTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_StockOptionAxis=drug_StockOptionsTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_SecondTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_ThirdTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_FourthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_StockOptionAxis=drug_StockOptionsThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_FifthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_StockOptionAxis=drug_StockOptionsFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_SixthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_SeventhTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_EighthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=drug_ThreeConsultantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_NinthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_TenthTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_VestingsAxis=drug_EleventhTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=drug_DirectorAndConsultantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=drug_ChiefMedicalOfficerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_DebtSettlementAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | drug_AgreementAxis=drug_EscrowAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |